Greenup Street Wealth Management LLC purchased a new stake in shares of Exelon Co. (NASDAQ:EXC – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 60,408 shares of the company’s stock, valued at approximately $2,274,000.
A number of other hedge funds have also recently made changes to their positions in the company. American National Bank & Trust boosted its stake in Exelon by 178.8% during the third quarter. American National Bank & Trust now owns 697 shares of the company’s stock valued at $28,000 after buying an additional 447 shares during the period. Ashton Thomas Securities LLC bought a new stake in shares of Exelon during the 3rd quarter valued at about $32,000. Versant Capital Management Inc grew its holdings in shares of Exelon by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 1,047 shares of the company’s stock worth $39,000 after purchasing an additional 379 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new position in shares of Exelon in the second quarter worth approximately $57,000. Finally, UMB Bank n.a. raised its stake in Exelon by 92.7% in the third quarter. UMB Bank n.a. now owns 1,528 shares of the company’s stock valued at $62,000 after purchasing an additional 735 shares in the last quarter. 80.92% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Guggenheim raised shares of Exelon from a “neutral” rating to a “buy” rating in a research note on Thursday, January 23rd. Scotiabank raised their price target on Exelon from $40.00 to $42.00 and gave the company a “sector perform” rating in a research report on Thursday, December 12th. Morgan Stanley reduced their price objective on Exelon from $46.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Friday, November 22nd. Evercore ISI raised Exelon from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $43.00 to $44.00 in a report on Tuesday, January 21st. Finally, Barclays reduced their price target on shares of Exelon from $44.00 to $42.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 22nd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.13.
Exelon Trading Up 3.4 %
NASDAQ:EXC opened at $40.71 on Tuesday. The firm has a market capitalization of $40.91 billion, a P/E ratio of 16.75, a P/E/G ratio of 2.61 and a beta of 0.55. Exelon Co. has a 52 week low of $33.35 and a 52 week high of $41.19. The company has a quick ratio of 0.97, a current ratio of 1.09 and a debt-to-equity ratio of 1.66. The company has a fifty day moving average of $38.12 and a 200 day moving average of $38.42.
Exelon (NASDAQ:EXC – Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. Exelon had a net margin of 10.60% and a return on equity of 9.47%. The company had revenue of $6.15 billion during the quarter, compared to analyst estimates of $5.85 billion. During the same period in the prior year, the business posted $0.67 earnings per share. Exelon’s revenue for the quarter was up 2.9% on a year-over-year basis. On average, research analysts predict that Exelon Co. will post 2.46 earnings per share for the current year.
Exelon Profile
Exelon Corporation, a utility services holding company, engages in the energy distribution and transmission businesses in the United States and Canada. The company is involved in the purchase and regulated retail sale of electricity and natural gas, transmission and distribution of electricity, and distribution of natural gas to retail customers.
Featured Articles
- Five stocks we like better than Exelon
- Top Biotech Stocks: Exploring Innovation Opportunities
- Sizing Up a New Opportunity for NVIDIA Investors
- Learn Technical Analysis Skills to Master the Stock Market
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Using the MarketBeat Dividend Yield Calculator
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.